CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lantern Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lantern Pharma Inc
1920 MCKINNEY AVENUE, 7TH FLOOR
Phone: (972) 277-1136p:972 277-1136 DALLAS, TX  75201  United States Ticker: LTRNLTRN
Business Summary
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Donald J.Keyser 70 11/1/2019 1/1/2018
President, Chief Executive Officer, Director Panna L.Sharma 52 8/29/2018 7/26/2018
Chief Financial Officer, Secretary David R.Margrave 63 11/1/2019 6/1/2018
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Lantern Pharma Australia Pty Ltd
Lantern Pharma Limited
LTRN
Starlight Therapeutics Inc.

General Information
Number of Employees: 21 (As of 12/31/2023)
Outstanding Shares: 10,784,725 (As of 11/1/2024)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 463973463
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024